Exact Sciences Posts Flat Q4 Revenues, Awaits Meeting with FDA about Cologuard | GenomeWeb

NEW YORK (GenomeWeb News) – Exact Sciences today reported flat revenues year over year for its fourth quarter, matching the consensus analyst estimate on the top line and beating it on the bottom line.

The Madison, Wis.-based molecular diagnostics company took in $1.0 million in revenues for the three months ended Dec. 31, 2013, the same as a year ago. Revenues for Q4 2013 and the year-ago period derived from licensing fees.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Ivanka Trump and Secretary of Education Betsy DeVos call on girls to pursue STEM careers, the Associated Press reports.

Some science companies will be taking part in next month's March for Science, Fortune reports.

In Genome Research this week: longitudinal study of Burkholderia cenocepacia isolates from cystic fibrosis patients, long-read assembly approach, and more.

Shale oil companies are turning to DNA sequencing to find spots to drill, Reuters reports.